How much does ritexitinib cost in China? The latest prices and medical insurance coverage in 2025

Ritlecitinib is an oral JAK inhibitor mainly used to treat moderate to severe alopecia areata, an autoimmune disease that causes hair loss. The drug helps regulate the immune response by inhibiting specific tyrosine kinase signaling pathways, thereby slowing or preventing hair follicle damage and restoring hair growth.

However, ritexitinib is not without side effects. Some patients may experience adverse reactions such as headache, fatigue, diarrhea, and upper respiratory tract infection. Most side effects are mild or moderate and usually resolve gradually during treatment. It is worth noting that long-term use of JAK inhibitors may have a certain impact on the immune system. Therefore, blood routine, liver and kidney function and other indicators need to be regularly monitored during treatment to ensure the safety of treatment.

Regarding price, the original drug of ritexitinib has been approved for marketing in China, but it is not yet included in the scope of medical insurance. According to market information, the common drug specification is 50mg*30 pills, and the price of each box may be as high as more than 3,000 yuan. In overseas markets, the price of the European version of the original drug is usually higher, and each box may sell for more than 10,000 yuan, which is greatly affected by exchange rate changes. In addition, there are some generic drugs available in the overseas market, such as the version produced in Laos. Its main ingredients are roughly the same as the original drugs, and the price is relatively low, about more than 1,000 yuan per box.

It should be noted that since ritexitinib is a new drug, the market price may fluctuate with time and supply. Therefore, patients are advised to consult a doctor or pharmacist before purchasing and pay attention to the latest market developments. At the same time, although the drug is not currently covered by medical insurance, with the increase in patients using it and the accumulation of relevant clinical data, it may be included in the scope of medical insurance reimbursement in the future, which will be of great help to the financial burden of patients.

Reference materials:https://www.litfulo.com/